Essentialis

Essentialis is a pharmaceutical company focused on the development of breakthrough medicines for the treatment of cardiovascular and metabolic diseases.

The company's portfolio of products is targeted at the ATP-sensitive potassium channel, a metabolically-regulated membrane protein whose modulation has the potential to impact a wide range of cardiovascular and metabolic diseases.

The company's lead product is in phase II studies in dyslipidemic subjects and is entering a phase I study in type I diabetes mellitus subjects.